The Ataxin 2 pipeline drugs market research report outlays comprehensive information on the Ataxin 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ataxin 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, and Genetic Disorders which include the indications Amyotrophic Lateral Sclerosis, and Spinocerebellar Ataxia (SCA). It also reviews key players involved in Ataxin 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Ataxin 2 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 2, and 2 respectively.
Ataxin 2 overview
Ataxin 2 is a protein encoded by the ATXN2 gene, and its involvement in various cellular processes has garnered attention due to its association with certain neurodegenerative disorders. The protein contains polyglutamine (polyQ) repeats, and expansions of these repeats have been linked to the development of certain neurodegenerative conditions, including spinocerebellar ataxia type 2 (SCA2). Ataxin 2 is widely expressed in various tissues, with higher levels observed in the brain, particularly in regions such as the cerebellum. In the context of neurodegenerative diseases, expanded polyQ repeats in Ataxin 2 can lead to protein misfolding and aggregation, contributing to the pathogenesis of SCA2. Additionally, Ataxin 2 has been implicated in other neurodegenerative conditions, such as amyotrophic lateral sclerosis (ALS).
For a complete picture of Ataxin 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
